Doxorubicin Completed Phase 1 Trials for Malignant Lymphomas Basic Science

IndicationsStatusPurposePhase
CompletedBasic Science1
clinicaltrials.gov IdentifierTitleDrugs
NCT01831505Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents